1	Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with
2	Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine
3	batch-to-batch consistency in Indonesian children and adults
4	
5	Eddy Fadlyana <sup>1</sup> , Meita Dhamayanti <sup>1</sup> , Rodman Tarigan <sup>1</sup> , Susantina Prodjosoewojo <sup>2</sup> , Andri Reza
6	Rahmadi <sup>2</sup> , Rini Mulia Sari <sup>3</sup> , Kusnandi Rusmil <sup>1</sup> , Cissy B Kartasasmita <sup>1</sup>
7	
8	<sup>1</sup> Department of Child Health, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin
9	Hospital, Bandung, Indonesia
10	<sup>2</sup> Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin
11	Hospital, Bandung, Indonesia
12	<sup>3</sup> Surveillance and Clinical Trial Division, PT Bio Farma, Bandung, Indonesia
13	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 15 Abstract

#### 16 Background

One of the newest strategies developed by the Global Influenza Strategy has been to broaden the composition of the current influenza vaccine formulations from trivalent products to quadrivalent products. This study aimed to assess the immunogenicity and safety of Quadrivalent Influenza HA vaccine (QIV) compared with Trivalent Influenza HA vaccine (TIV) and to evaluate three consecutive batches of QIV equivalence in Indonesian children and adults.

#### 22 Methods and findings

This was an open-labeled, bridging clinical study involving unprimed healthy children and adults 23 aged 9-40 years. A total of 540 subjects were enrolled in this study and randomized into four 24 25 arm groups. Each subject received one dose of TIV or QIV with three different batch codes. Serology tests were performed at baseline and 28 days after vaccination. Hemagglutination 26 inhibition (HI) antibody titers were analyzed for Geometric Mean Titer (GMT), seroprotection, 27 and seroconversion rates. Solicited, unsolicited, and serious adverse events were observed up to 28 28 days after vaccination. A total of 537 subjects completed the study per protocol and were 29 analyzed for immunogenicity criteria. All randomized subjects were analyzed for safety criteria. 30 The percentage of the subjects with anti-HI titer  $\geq$ 1:40 28 days after QIV vaccination was 99.5% 31 for A/H1N1; 99.5% for A/H3N2; 93.1% for B/Texas, and 99.0% for B/Phuket. The 32 seroprotection, GMT, and seroconversion rates of QIV were not significantly different from 33 those of TIV for the common vaccine strains (p > 0.01) and were significantly different from 34 those of TIV for the added B/Phuket strains (p < 0.01). Most solicited injection-site and systemic 35 reactions with either vaccine were mild to moderate and resolved within a few days. 36

#### 37 Conclusions

- 38 QIV was immunogenic and well-tolerated and had immunogenicity and safety profiles compared
- 39 with TIV for all common strains. The immunogenicity of the three batches of QIV was equivalent
- 40 for the four strains.
- 42 Keywords: children, adult, immunogenicity, Quadrivalent Influenza HA vaccine, safety,
- 43 Trivalent Influenza HA vaccine
- 44 Clinical Trial registration: NCT03336593

# 57 Introduction

Influenza is an acute viral illness of the respiratory tract and poses a substantial public health 58 burden in terms of morbidity, mortality, and costs. The World Health Organization (WHO) 59 reported that 3-5 million cases of severe influenza occur each year worldwide, resulting in about 60 290,000 to 650,000 related deaths per year. One of the goals of the Global Influenza Strategy for 61 2019–2030 is to reduce the burden of seasonal influenza by promoting research and innovation 62 for improved influenza vaccines [1]. Annual influenza immunization is recommended in elderly 63 subjects, children aged six months or more, pregnant women, and individuals with chronic 64 conditions, such as respiratory/heart/liver diseases, diabetes, or a weakened immune system. 65 These categories are at heightened risk of influenza-related complications and mortality [2]. 66

Internationally available vaccines for controlling seasonal influenza are safe and effective 67 and have the potential to prevent significant annual morbidity and mortality. The WHO annually 68 69 recommends composing vaccines based on global virological surveillance. Annual Trivalent influenza HA vaccines (TIVs) contain two influenza A strains (H1N1 and H3N2) and only one 70 influenza B virus [3]. Therefore, the effectiveness of TIVs depends on the degree of matching 71 between the vaccine strain and circulating viral strains. In the last two decades, four major and 72 at least eight minor mismatches between vaccine and circulating B viruses have occurred in the 73 74 northern hemisphere, thus impairing the performance of TIVs [4]. Specifically, Ambrose et al. observed that a B-mismatch between vaccine and circulating strains occurred in Europe in 5 of 75 10 seasons between 2001 and 2011 [5]. 76

In February 2009, the Food and Drug Administration (FDA), for the first time, considered the inclusion of an additional influenza B strain in the antigenic composition of seasonal influenza vaccines to minimize the impact of B strain-mismatch on vaccine effectiveness [6]. Subsequently, in February 2012, the WHO recommended the production of Quadrivalent Influenza HA vaccines (QIVs) for seasonal immunization. In 2012, the European Medicines

Agency (EMA) also highlighted the need for a quadrivalent vaccine that could overcome the lack of protection against the influenza B lineage not present in the trivalent vaccine. Finally, in February 2013, the WHO issued its first guidelines recommending that both expected B strains be included in the vaccine composition [7,8].

Bio Farma conducted several studies on seasonal TIVs between 2008 and 2014. The results 86 of these studies were consistent. TIVs were well-tolerated and induced high antibody titer against 87 88 influenza antigens and no serious adverse events (AEs) during the study [9-13]. This was the first QIV study conducted by Bio Farma on subjects aged 9-40 years in Indonesia. QIVs that 89 90 could potentially provide wider protection against influenza B viruses are becoming available, and recommendations should not be limited to trivalent vaccine formulations [3]. This study 91 aimed to assess the immunogenicity and safety of QIV compared with TIV and to evaluate batch-92 to-batch consistency in three consecutive batches of QIV. 93

# 94 Materials and methods

### 95 2.1 Study design

96 This was an experimental open-labeled, four arm bridging study. The study was a collaboration 97 between the Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, and PT 98 Bio Farma (Persero), Indonesia. This study was approved by the Research Ethics Committee of 99 the Faculty of Medicine, Universitas Padjadjaran, and conducted in accordance with the 100 Declaration of Helsinki and the International Conference on Harmonization Good Clinical 101 Practice guidelines. Written informed consent was obtained from the participants or their parents 102 before performing any study-specific procedure.

### 103 2.2 Study subjects

A total of 540 subjects were enrolled in this study. Subjects were enrolled from 3 primary care
 centers in Bandung City, Ibrahim Adjie Primary Health Center, Puter Primary Health Center,

and Garuda Primary Health Center, from October 2017 to June 2018. The primary inclusion 106 criteria included healthy children and adults aged 9-40 years committed to complying with study 107 instructions and trial schedules. Subjects were not eligible if they presented with mild, moderate, 108 or severe illness with a fever (axillary temperature  $\geq 37.5^{\circ}$ C). Other exclusion criteria included 109 allergic to egg, chicken protein, or other vaccine components and a history of blood disorders 110 contraindicating intramuscular injection. 111

2.3 112

# **Randomization and blinding**

113 For each subject recruited, the inclusion number was allocated in the chronological order of the subject, which was included in the trial from I-001 to I-180 (for the 9–12-year age group), II-001 114 to II-180 (for the 13–17-year age group), and III-001 to III-180 (for the 18–40-year age group). 115 The subjects were randomized into treatment groups. The doctor strictly followed the list of 116 randomization provided by Bio Farma. Treatment was allocated in accordance with a 117 118 randomization list so that each randomization number corresponded to only one strictly randomly assigned treatment group (QIV batch A, QIV batch B, QIV batch C, and TIV). 119

#### Vaccines and vaccination schedule 2.4 120

The QIV vaccine was formulated by PT Bio Farma (Persero), Indonesia, using bulks imported 121 122 from Japan. The investigational QIV contained 15 µg HA from each of 4 strains, A/California/7/2009 (X-179A) (H1N1) pdm09n, A/Hong Kong/4801/2014 (X-263) (H3N2), 123 B/Texas/2/2013, and B/Phuket/3073/2013, in a 0.5 ml dose, with batch numbers A: 3070117, B: 124 3070217, and C: 3070317. TIV contained 15 µg HA of each of 3 strains, A/California/7/2009 125 (X-179A) (H1N1) pdm09n, A/Hong Kong/4801/2014 (X-263) (H3N2), and B/Texas/2/2013, in 126 0.5 ml dose. Each subject received one dose (0.5 ml) of TIV or QIV with different batch numbers: 127 3070117, 3070217, and 3070317 for batches A, B, and C, respectively, according to the 128 randomization. 129

# 130 Sample size and study analysis

The sample size was determined based on a 95% confidence interval (CI) and a test power of 131 80%. The required sample size was 115 in each group, with 10% dropout anticipation. With the 132 assumption that not all the subjects could complete the study, the total number of subjects was 133 added at least 10% from the minimum requirement  $(1/1 - 0.1) \times 115 = 128$ . Demographic data 134 were expressed as mean, standard deviation, and range values. Immunogenicity analyses were 135 performed on the per protocol population. Analysis of Geometric Mean Titer (GMT), 136 137 seroprotection, and seroconversion rates between the vaccine groups was performed using the Chi-square, McNemar, or Wilcoxon tests. Values of p < 0.05 indicated statistically significant 138 differences between groups. 139

The safety analyses were based on the intention-to-treat population analyses. The safety 140 data were collected up to 28 days after the vaccination. The subjects were provided with a diary 141 card to record the appearance, duration, and intensity (mild, moderate, or severe) of any solicited 142 AE (local pain, redness, swelling, induration, fever, fatigue, and myalgia) and unsolicited AE. 143 Local pain was graded as mild (mild pain at the injection-site when touched), moderate (pain 144 145 with movements), and severe (significant pain at rest). Redness, induration, and swelling intensity were measured using a plastic bangle and categorized as mild (<5 cm), moderate (5-10 146 cm), and severe (>10 cm). Fever was graded as mild (38.0°C-38.4°C), moderate (38.5°C-147 38.9°C), and severe ( $\geq$ 39.0°C). Fatigue, myalgia, and unsolicited events were graded as mild (no 148 interference with activity), moderate (some interference with activity), and severe (prevents daily 149 activity, requires medical intervention). 150

# 151 **Results**

# **3.1 Demographics and baseline characteristics**

#### 153 Table 1. Demographic characteristics of study participants

	Batch A	Batch B	Batch C	TIV
Charateristics	(n = 135)	(n = 135)	(n = 135)	(n = 135)
Sex, n (%)				
Male	67 (49.6)	67 (49.6)	57(42.2)	64 (47.4)
Female	68 (50.4)	68 (50.4)	78 (57.8)	71 (52.6)
Age (y)				
Mean ± standard deviation	$17.21 \pm 7.64$	$17.70\pm8.48$	$17.74\pm8.31$	$17.18 \pm 8.27$
Median	15	14	14	14
Range	9–39	9–40	9–40	9–39

154

In this study, 405 and 135 subjects were enrolled in the QIV and TIV groups, respectively. Of 155

the 405 subjects in the QIV group, three were excluded from immunogenicity analysis because 156

of protocol non-compliance (Fig 1). The demographic characteristics of study participants 157

showed a fair distribution in gender and age (Table 1). 158

Fig 1. Participant disposition. 159

#### **3.2 Immunogenicity** 160

161 Table 2 shows a comparison of the percentage of subjects with anti-HI titer  $\geq 1:40$  28 days after

QIV and TIV. No difference in seroprotection was observed between one dose of QIV and TIV, 162

except for B/Phuket/3073/2013. 163

Strain	Pre-imm	Pre-immunization $p^*$ Post-immunization		p*		
	QIV ( <i>n</i> = 402)	TIV ( <i>n</i> = 135)		QIV ( <i>n</i> = 402)	TIV ( <i>n</i> = 135)	
A/H1N1						
≥1:40 HI, <i>n</i>	274	82	0.115	400	133	0.264
% (95% CI)	68.2 (63.4–72.5)	60.7 (52.5–69.0)		99.5 (98.2–99.9)	98.5 (94.8–99.6)	
A/H3N2						
≥1:40 HI, <i>n</i>	267	92	0.712	400	132	0.104
% (95% CI)	66.4 (61.7–70.9)	68.1 (60.3–76.0)		99.5 (98.2–99.9)	97.8 (93.7–99.2)	
B/Texas						
≥1:40 HI, <i>n</i>	146	53	0.540	374	124	0.647
% (95% CI)	36.3 (31.8–41.4)	39.3 (31.0–47.5)		93.0 (90.1–95.1)	91.9 (86.0–95.4)	
B/Phuket						
≥1:40 HI, <i>n</i>	249	76	0.246	398	123	<0,001
% (95% CI)	61.9 (57.1–66.6)	56.3 (47.9–64.7)		99.0 (97.5–99.6)	91.1 (85.1–94.8)	

#### 165 Table 2. Influenza seroprotection rate before and 28 days after immunization.

166 \*Mann–Whitney test.

Fig 2 shows a comparison of GMT between subjects who received QIV and TIV. No significant differences in GMT were observed between one dose of QIV and TIV in the 9–40year-old subjects for A/California/7/2009 (X-179A) (H1N1) pdm09, A/Hong Kong/4801/2014 (X-263) (H3N2), and B/Texas/2/2013 (p = 0.322, p = 0.536, and p = 0.378, respectively). However, a significant difference in GMT was observed between one dose of QIV and TIV for strain B/Phuket/3073/2013 (p < 0.001).

Fig 2. Hemagglutination inhibition (HI) Geometric Mean Titers (GMT) before and 28 days after
QIV and TIV immunization.

175

176 The transition from seronegative to seropositive is defined as a pre-vaccination titer <1:40

177 HI units and a post-vaccination titer  $\geq$ 1:40 HI units. Seroconversion was also defined as

increasing antibody titer  $\geq 4$  times and transition from seronegative to seropositive (Table 3).

#### 179 **Table 3. Differences in seroconversion rates.**

		Increa	asing antibody titer	•		Transition	from seronegative	to	
			≥4 times <sup>a</sup>			S	eropositive <sup>b</sup>		
Strain	n (%)					(%) <sup>c</sup>			
	QIV	TIV	%Diff	р	QIV	TIV	Diff	p <sup>d</sup>	
			(95% CI)				(95% CI)		
A/H1N1	333 (82.2)	115 (85.2)	-3.0 (-9.4; 4.8)	0.525	98.4%	96.2%	2.2 (-0.8; 6.7)	0.582	
A/H3N2	331 (81.7)	113 (83.1)	-1.4 (-8.1; 6.6)	0.717	98.5%	93.0%	5.5 (1.6; 10.8)	0.092	
B/Texas	349 (86.1)	114 (84.4)	1.7 (-4.6; 9.4)	0.489	89.1%	86.6%	2.5 (-3.4; 9.7)	0.541	
B/Phuket	335 (82.7)	56 (41.5)	41.2 (31.9; 49.9)	< 0.001	97.4%	79.7%	17.7 (11.0; 24.9)	< 0.001	

180 CI, confidence interval.

181 <sup>a</sup>Number of subjects (*n*) on increasing antibody titer for group QIV = 402 and group TIV = 135.

<sup>b</sup>Number of subjects (*n*) on transition from seronegative to seropositive for each group, and each strain was based

183 on the number of seronegative subjects at baseline (pre-vaccination).

184 <sup>c</sup> Percentage (%) defined as the percentage of subjects with anti-HI titer <1:40 HI (seronegative) at baseline and

**185**  $\geq$ 1:40 HI (seropositive) after vaccination.

186 <sup>d</sup> p value based on the Fisher exact test

187

#### 188 Table 4. QIV batch-to-batch comparison.

Strain	Comparison	Comparison GMT	
		post-vaccination	
		ratio (95% CI)	
A/H1N1	Batch A vs. batch B	1.030 (0.996–1.061)	Yes
	Batch A vs. batch C	1.020 (0.976–1.072)	Yes
	Batch B vs. batch C	1.082 (0.988–1.176)	Yes
	Strain A/H1N1	StrainComparisonA/H1N1Batch A vs. batch BBatch A vs. batch CBatch B vs. batch C	Strain         Comparison         GMT           post-vaccination         post-vaccination         ratio (95% CI)           A/H1N1         Batch A vs. batch B         1.030 (0.996–1.061)           Batch A vs. batch C         1.020 (0.976–1.072)           Batch B vs. batch C         1.082 (0.988–1.176)

	A/H3N2	Batch A vs. batch B	1.074 (0.996–1.152)	Yes
		Batch A vs. batch C	1.027 (0.971–1.083)	Yes
		Batch B vs. batch C	0.987 (0.928–1.045)	Yes
	B/Texas	Batch A vs. batch B	0.951(0.941-1.061)	Yes
		Batch A vs. batch C	1.003 (0.867–1.138)	Yes
		Batch B vs. batch C	1.107 (0.979–1.236)	Yes
	B/Phuket	Batch A vs. batch B	1.076 (1.004–1.147)	Yes
		Batch A vs. batch C	1.089 (1.019–1.159)	Yes
		Batch B vs. batch C	1.045 (0.960–1.129)	Yes
13–17 years	A/H1N1	Batch A vs. batch B	1.010 (0.958–1.063)	Yes
<i>n</i> = 132		Batch A vs. batch C	0.981 (0.938–1.023)	Yes
		Batch B vs. batch C	0.982 (0.944–1.021)	Yes
	A/H3N2	Batch A vs. batch B	0.997 (0.925–1.068)	Yes
		Batch A vs. batch C	1.023 (0.949–1.096)	Yes
		Batch B vs. batch C	1.053 (0.984–1.121)	Yes
	B/Texas	Batch A vs. batch B	1.025 (0.916–1.133)	Yes
		Batch A vs. batch C	0.972 (0.881–1.064)	Yes
		Batch B vs. batch C	1.000 (0.913–1.087)	Yes
	B/Phuket	Batch A vs. batch B	1.009 (0.948–1.070)	Yes
		Batch A vs. batch C	0.971 (0.909–1.034)	Yes
		Batch B vs. batch C	0.984 (0.913–1.055)	Yes
18–40 years	A/H1N1	Batch A vs. batch B	1.051 (0.982–1.120)	Yes
<i>n</i> = 135		Batch A vs. batch C	1.073 (0.996–1.150)	Yes
		Batch B vs. batch C	1.036 (0.975–1.097)	Yes
	A/H3N2	Batch A vs. batch B	1.123 (1.034–1.211)	Yes
		Batch A vs. batch C	1.062 (0.968–1.155)	Yes
		Batch B vs. batch C	0.985 (0.889–1.081)	Yes
	B/Texas	Batch A vs. batch B	1.028 (0.927–1.129)	Yes
		Batch A vs. batch C	1.064 (0.958–1.169)	Yes
		Batch B vs. batch C	1.067 (0.969–1.165)	Yes

	B/Phuket	Batch A vs. batch B	1.065 (0.987–1.144)	Yes
		Batch A vs. batch C	1.084 (0.998–1.170)	Yes
		Batch B vs. batch C	1.042 (0.967–1.117)	Yes
All age	A/H1N1	Batch A vs. batch B	1.029 (0.996–1.061)	Yes
(9-40 years)		Batch A vs. batch C	1.046 (1.003–1.089)	Yes
<i>n</i> = 402		Batch B vs. batch C	1.030 (0.989–1.070)	Yes
	A/H3N2	Batch A vs. batch B	1.066 (1.020–1.111)	Yes
		Batch A vs. batch C	1.037 (0.994–1.080)	Yes
		Batch B vs. batch C	1.008 (0.964–1.051)	Yes
	B/Texas	Batch A vs. batch B	1.001 (0.941–1.061)	Yes
		Batch A vs. batch C	1.014 (0.950–1.078)	Yes
		Batch B vs. batch C	1.059 (0.998–1.119)	Yes
	B/Phuket	Batch A vs. batch B	1.050 (1.010–1.090)	Yes
		Batch A vs. batch C	1.049 (1.006–1.091)	Yes
		Batch B vs. batch C	1.024 (0.980–1.067)	Yes

189 Age 9–12 years: n = 45 for each QIV batch A, B, and C group.

190 Age 13–17 years: n = 44 for QIV batch A group, n = 43 for QIV batch B group, and n = 45 for QIV batch C group.

191 Age 18–40 years: n = 45 for each QIV batch A, B, and C group.

192

Batch-to-batch equivalence for each strain was concluded if the two-sided 95% CI of each

strain GMT ratio of the compared batches was between 0.67 and 1.5 (Table 4) [14].

### 195 **3.3 Safety**

196 Solicited and unsolicited post-vaccination AEs were categorized as immediate (within 30 min),

intermediate (30 min to 72 h), and delayed (72 h to 28 days) reactions (Figs 3 and 4).

198 Fig 3. Intensity of reported local and systemic adverse events (AEs).

199

200 Most local and systemic AEs reported in the QIV and TIV groups had mild intensity. Mild 201 pain was the most local adverse reaction, which occurred in 15.3% and 17.8% of the subjects in

the QIV and TIV groups, respectively. Mild myalgia was the most systemic adverse reaction,

which occurred in 13.6% and 9.6% of the subjects in the QIV and TIV groups, respectively.

Fig 4. Intensity of reported local and systemic AEs on each QIV batch.

# 205 **Discussion**

This study was conducted on subjects aged 9-40 years, while a previous study by Dhamayanti 206 et al. was conducted on infants to children aged 8 years [15]. The HI data showed a strong 207 208 serological response for each of the shared influenza strains in the QIV and TIV groups and the percentage of subjects in the QIV group achieving a serum HI titer  $\geq$ 40. In this study, in the age 209 210 group of 9-40 years, the QIV induced comparable immune responses to TIV for A strains and the B lineage common to both QIV and TIV. The protectivity/seroprotection rate of QIV was 211 defined as the percentage of participants with an HI titer >40 for A/California/7/2009 (X-179A) 212 (H1N1) pdm09, A/Hong Kong/4801/2014 (X-263) (H3N2), B/Texas/2/2013, 213 and B/Phuket/3073/2013 of QIV (99.5%; 99.5%; 93.1%; 99.0%) and TIV (98.5%; 97.8%; 91.9%; 214 91.1%). The immunogenicity based on seroprotection rates of a candidate QIV was not 215 significantly different from TIV for shared vaccine strains (p > 0.01) and was significantly 216 different from TIV with respect to the added B strains (B/Phuket/3073/2013) (p < 0.01). The 217 same result was observed for the GMT as well. 218

The inclusion of a fourth strain in QIV did not interfere with the EMA criteria for immune responses in adult vaccine recipients. In adults, post-vaccination seroprotection rates were  $\geq$ 99%, seroconversion rates were  $\geq$ 59%, and post-vaccination/pre-vaccination GMT ratios were  $\geq$ 7.3 for all four vaccine strains. These data demonstrate that the presence of a second influenza B strain in QIV does not negatively affect the immune response to the other strains. Moreover, the immune responses to all strains contained in the two vaccines were robust, with the highest responses to the A/California/7/2009 (H1N1) strain.

226

The seroconversion rates regarding the percentage of subjects with increasing antibody

titer  $\geq$ 4 times and transition of seronegative to seropositive and of QIV were not significantly 227 different from those of TIV. The superior QIV immunogenicity is expected to correspond with 228 superior protection against influenza B relative to TIV in a season when there is lineage mismatch 229 or cocirculation of two influenza B lineages. These findings are similar to those of the meta-230 analysis study by Moa in 2015, which confirmed that the inactivated QIV used in the studies in 231 adults had similar efficacy against the three strains shared in common with the TIV (A/H1N1, 232 A/H3N2, and the B lineage included in the TIV) and statistically significant superior efficacy 233 against the B lineage not included in the TIV. The presence of a second influenza B strain in 234 235 QIV did not negatively affect the immune response to the other strains. The addition of a second B strain in QIV might enhance the protective efficacy of influenza vaccines as it would reduce 236 the undesirable mismatch between the recommended B strain for TIV and the one predominantly 237 circulating [16–17]. 238

This study also showed that the immunogenicity of the three batches of QIV was equivalent 239 for the four strains. Batch-to-batch equivalence of all three batches of QIV was demonstrated for 240 all four strains. The seroprotection rates of three batches for A/California/7/2009 (X-179A) 241 A/Hong Kong/4801/2014 (X-263) (H3N2), B/Texas/2/2013, (H1N1) pdm09, 242 and B/Phuket/3073/2013 were (99.3; 100; 99.3), (99.3; 99.2; 100), (88.8; 95.5; 94.8), and (98.5; 100; 243 98.5), respectively. The increase in the overall post-vaccination GMTs for each pair of batches 244 for each strain was not different. 245

During this study, no serious AEs related to the vaccine were observed. This study found comparable reactogenicity and safety profiles between the QIV candidate and the TIV in both adult and adolescent groups. Both vaccines were well-tolerated by both age groups. Local and systemic reactogenicity profiles were also similar between the vaccine groups. Most reactions were mild or moderate in severity and lasted for 1–3 days. Most solicited injection-site and systemic reactions with either vaccine were mild to moderate and resolved within a few days.

Injection-site pain was the most frequently reported solicited local event, and fatigue and myalgia were the commonly reported solicited systemic events among the studies. A metaanalysis study by Moa in 2015 showed a comparable safety profile between QIV and TIV. However, QIV had a slightly increased frequency of injection-site pain compared with TIV, and no statistically significant difference was observed in the overall rate of AEs [16].

The QIV and TIV groups showed similar rates of systemic AEs. In both vaccine groups, mild myalgia was the most frequent systemic AE. These findings are similar to those reported by Wang et al. [18]. The incidence of fever was similar with both vaccines, which is consistent with the results of a previous study [19].

Frequencies of unsolicited AEs in the 28 days following vaccination with QIV were similar 261 between the adult and adolescent groups. These data are consistent with the results of a meta-262 analysis of five randomized clinical trials, demonstrating no significant difference between QIV 263 and TIV in terms of the frequency of aggregated local and systemic AEs within 7 days after 264 vaccination [16]. The trials reported that the rate of both local and systemic AEs was transient, 265 short-lived, and resolved within 1–3 days in both vaccine groups. No vaccine-related serious 266 AEs or deaths were associated with the vaccines. Although QIV had a slight increase in local 267 reaction (injection-site pain) compared with TIV, the potential benefit of QIV is considered 268 greater with regard to improved protection from infection in the population [16]. 269

270 QIV and TIV have similar reactogenicity and AE profiles, with no apparent adverse effects 271 on the tolerability of the higher antigen content in QIV (60  $\mu$ g HA for 4 strains compared with 272 22.5  $\mu$ g for 3 strains in the TIV). Furthermore, the safety profiles of the two vaccine groups were 273 comparable. The results of this study demonstrated that the additional B strain in QIV did not 274 compromise safety compared with TIV. These findings are similar to those of the meta-analysis, 275 which did not find any significant differences in the systemic events, headache, and myalgia 276 between the two vaccines [16].

In this study, immunogenicity was only assessed 28 days after the last vaccination. Hence, we do not know the duration of antibody responses to the 4 strains. Further study is needed to evaluate the antibody persistence of the QIV.

# 280 **Conclusion**

In conclusion, this study demonstrated that QIV can be reproducibly manufactured to yield a well-tolerated, safe, and immunogenic vaccine in people aged 9–40 years and that it met all EMA immunogenicity criteria in adults. In adults, inactivated QIV induced comparable immune responses to TIV for A strains and the B lineage common to both QIV and TIV.

These data support the use of Bio Farma QIV for seasonal vaccination in children and adult subjects, which may enhance the protection against influenza and decrease the burden associated with influenza complications. The immunogenicity of the three batches of QIV was equivalent for all four strains.

## 289 Funding support

Funding for this trial was provided by PT Bio Farma Indonesia, no 04310/DIR/XI/2017, PO00017403

# 292 **Role of the sponsor**

PT Bio Farma Indonesia was involved in the study design, data collection, data analysis andpreparation of the manuscript.

# 295 Acknowledgment

We would like to thank Dr. Iskandar, the Director of Bio Farma, for supporting this study. Thanks
to Dr. Novilia S. Bachtiar, dr., M.Kes who has passed away for her contribution during various
stages of the paper preparation. We would also like to thank the participants, Rita Verita Sri
Hasniarty, the Head of Bandung District Health Office, Nitta Kurniati, the Head of Garuda
Primary Health Center, and her staff, Siti Nurhasijatiningsih, the Head of Ibrahim Adjie Primary

Health Center, and her staff, and Slyvie Virginati, the Head of Puter Primary Health Center, and her staff for their work in this study. We also thank Mr. Hadyana Sukandar for his statistical work in this study and acknowledge the Indonesian National AEFI Committee as the auditor of serious AEs in this study. We would also like to express our appreciation to the staff at the Clinical Research Unit of Growth Development-Social Pediatric Division for the invaluable administrative assistance.

# 307 **Contribution statement**

Eddy Fadlyana: Conceptualization, Supervision, Data curation, Formal analysis, Funding 308 acquisition, Investigation, Methodology, Project administration, Resources, Visualization, 309 Writing – original draft, Writing – review & editing. Meita Dhamavanti: Conceptualization, 310 Supervision, Data curation, Formal analysis, Investigation, Methodology, Resources, Writing -311 review & editing. Rodman Tarigan, Susantina Prodjosoewojo, Andri Reza Rahmadi: 312 Conceptualization, Data curation, Formal analysis, Investigation, Resources, Writing - review 313 & editing. Rini Mulia Sari: Conceptualization, Data curation, Funding acquisition, 314 315 Methodology, Project administration, Resources, Validation. Kusnandi **Rusmil:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, 316 Methodology, Project administration, Resources, Supervision, Validation, writing - review & 317 editing. Cissy B. Kartasasmita: Conceptualization, Methodology, Writing - review & editing. 318

# 319 Ethics approval and consent to participate

This trial was approved by Research Ethics Committee Universitas Padjadjaran, Bandung (no.887/UN6.C.10/PN/2017). Written informed consent was obtained from the child's parents and adult participants before performing any study procedure.

# 323 Competing interests

324 Novilia Sjafri Bachtiar and Rini Mulia Sari are employees of PT Bio Farma at the time of the

325 conduct of this study and manuscript preparation.

# 326 **Reference**

- 327 [1] World Health Ogranization. Strategic Objectives and Actions. 2018. Available from:
- https://apps.who.int/iris/rest/bitstreams/1137738/retrieve (accessed March 30, 2020).
- 329 [2] Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, Bresee JS.
- Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep
  2016;65:1–54. doi:10.15585/mmwr.rr6505a1.
- 332 [3] World Health Ogranization. Weekly Epidemiological Record. WHO. 2012: 87(47): 461–
- 333 76. Available from:
- https://apps.who.int/iris/bitstream/handle/10665/241994/WER8747.PDF?sequence=1&i
  sAllowed=y (accessed March 30, 2020).
- Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. R
  Soc 2001:1861–70. doi:10.1098/rstb.2001.0999.
- Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin
  Immunother 2012;8:81–8. doi:10.4161/hv.8.1.17623.
- Food and Drug Administration Center. Summary Minutes Vaccines and Related
   Biological Products Advisory Committee. 2009. Available from: https://wayback.archive it.org/7993/20170113080624/http://www.fda.gov/downloads/AdvisoryCommittees/Com
- 343 mitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologi
- 344 calProductsAdvisoryCommittee/UCM167154.pdf (accessed March 31, 2020).
- World Health Ogranization. Summary of status of development and availability of
  influenza B (Yamagata and Victoria lineage) candidate vaccine viruses\* and potency
  testing reagents. 2011. Available from:
  http://www.who.int/influenza/vaccines/virus/candidates reagents/summary b cvv reag

- ents\_11\_aug\_2011.pdf (accessed March 31, 2020).
- Tisa V, Barberis I, Faccio V, Paganino C, Trucchi C, Martini M, Ansaldi F. Quadrivalent
  influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg
  2016;57:E28-33.
- 353 [9] Rusmil K, Fadlyana E, Dhamayanti M, Gunadi R BN. Protectivity and Safety of Influenza
- HA Vaccine (PT Bio Farma) in Adolescents and Adults, Poster Presentation Indonesian
  Influenza Foundation Symposium 2013. 2013.
- Fadlyana E, Rusmil K, Bachtiar NS, Gunadi R SH. Immunogenicity and safety of a
  trivalent inactivated influenza vaccine. Paediatr Indones 2011;51:22–8.
- Irie S, Fujieda M, Ito K, Ishibashi M, Takamizawa T, Ishikawa T et al. Immune response
  against inactivated influenza vaccine in children under four years old. J Infect Dis
  2007;81:284–90.
- [12] Soedjatmiko S, Medise BE, Gunardi H, Sekartini R, Satari HI, Hadinegoro SR, Bachtiar
  NS, Sari RM. Immunogenicity and Safety of a Trivalent Influenza HA Vaccine in
  Indonesian Infants and Children. Vaccine 2018; 36(16):2126-2132.
- 364 [13] University TRF for MD of O. Clinical Trial for BK-FLU on Healthy Adults. n.d.
- 365 [14] Food and Drug Administration Center. Clinical Data Needed to Support the Licensure of
  366 Seasonal Inactivated Influenza Vaccines. Guidance for Industry. 2007: 1-16. Available
  367 from:
- 368 https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Gui
- 369 dance-for-Industry--Clinical-Data-Needed-to-Support-the-Licensure-of-Seasonal-
- 370 Inactivated-Influenza-Vaccines.pdf. (accessed March 31, 2020)
- 371 [15] Dhamayanti M, Tarigan R, Fadlyana E, Prasetyo D, Amalia N, Rusmil VK, et al.
  372 Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children:
  373 An open-labeled, bridging, clinical study. Vaccine 2020;38:993–1000.

doi:10.1016/j.vaccine.2019.12.008.

- 375 [16] Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and
  376 safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and
  377 meta-analysis of randomised controlled trials. Vaccine 2016;34:4092–102.
  378 doi:10.1016/j.vaccine.2016.06.064.
- 379 [17] Ganczak M, Dubiel P, Drozd-Dąbrowska M, Hallmann-Szelińska E, Szymański K,
  380 Brydak LB. Quadrivalent influenza vaccine-induced antibody response and influencing
  381 determinants in patients ≥ 55 years of age in the 2018/2019 season. Int J Environ Res
  382 Public Health. 2019 Nov 14;16(22):4489. doi: 10.3390/ijerph16224489. PMID:
  383 31739554; PMCID: PMC6887788.
- Wang L, Chandrasekaran V, Domachowske JB, Li P, Innis BL, Jain VK. Immunogenicity
  and safety of an inactivated quadrivalent influenza vaccine in US children 6–35 months
  of age during 2013–2014: Results from a Phase II randomized trial. J Pediatric Infect Dis
  Soc 2016;5:170. doi:10.1093/JPIDS/PIV041.
- [19] Jain VK, Rivera L, Zaman K, Espos RA, Sirivichayakul C, Quiambao BP, et al. Vaccine
  for prevention of mild and moderate-to-severe influenza in children. N Engl J Med
- 390 2013;369:2481–91. doi:10.1056/NEJMoa1215817.



Fig 2. Hemagglutination inhibition (HI) Geometric Mean Titers (GMT) before and 28 days after QIV and TIV immunization.

# Figure 2



Fig 3. Intensity of reported local and systemic adverse events (AEs).

# Figure 3



Fig 4. Intensity of reported local and systemic AEs on each QIV batch.

# Figure 4





 Exluded from analysis (Protocol noncompliant, n=134)  Exluded from analysis (Protocol noncompliant, n=2)



Fig 1. Participant Disposition

